6 patents
Utility
Polymorphs of [2-(1H-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5-TRIMETHOXY)METHANONE and Its Salts
2 Nov 23
The invention encompasses polymorphs of [2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone and salts thereof.
Thomas Gary BIRD, Kester Gary BARNETTE, Mitchell S. STEINER
Filed: 27 Apr 23
Utility
Methods of Treating Influenza and Poxvirus Viral Infections
12 Oct 23
The present invention relates to methods of treating specific viral infections using compounds having anti-tubulin or tubulin disruption activity.
Mitchell S. STEINER, Kester Gary BARNETTE
Filed: 7 Apr 23
Utility
Methods of Prescreening and Treating Breast Cancers with Selective Androgen Receptor Modulators
18 Aug 22
This invention relates to methods of prescreening and treatment of a breast cancer in a subject, and the subject can be either a male or female subject, including methods of prescreening then treating: metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed treatments with selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), fulvestrant, cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio), trilaciclib, lerociclib), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), mTOR inhibitor (everolimus), poly ADP ribose polymerase (PARP) inhibitor (olaparib (Lynparza) or talazoparib (Talzenna)), human epidermal growth factor receptor 2 (HER2) kinase inhibitor (lapatinib, neratinib (Nerlynx), dacomitinib (Vizimpro), or tucatinib (Tukysa)), HER2 antibody (trastuzumab (Herceptin), pertuzumab (Perjeta), margetuximab-cmkb (Margenza)), HER2 antibody drug conjugate (HER2 ADC) (am-trastuzumab-deruxtecan-nxki (Enhertu), ado-trastuzumab emtansine (Kadcyla), or pertuzumab/trastuzumab/hyaluronidase-zzxf (Phesgo)), atezolizumab (Tecentriq) (PD-L1 blocking antibody), pembrolizumab (Keytruda) (PD-L1 blocking antibody), sacituzumab govitecan (Trodelvy) (antibody drug conjugate for TNBC), bevacizumab (Avastin), and/or sabizabulin or a pharmaceutically acceptable salt thereof; metastasis in a subject suffering from breast cancer; HER2-positive; and/or ER mutant expressing breast cancer, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound as described herein.
Mitchell S. Steiner, Kester Gary Barnette
Filed: 11 Feb 22
Utility
Methods of Treating Coronavirus
7 Oct 21
The present invention relates to methods of treating coronavirus infections using compounds having anti-tubulin or tubulin disruption activity.
Mitchell S. STEINER, Kester Gary BARNETTE
Filed: 5 Apr 21
Utility
COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
9 Sep 20
The invention provides compositions and methods for long term release of gonadotropin-releasing hormone (GnRH) antagonists and uses thereof.
Ravi KACKER, Mitchell S. STEINER, Jui-Chen LIN, Andrew Michael CERRO, Christopher A. RHODES
Filed: 20 May 20
Utility
Compounds for Treatment of Triple Negative Breast Cancer and Ovarian Cancer
25 Dec 19
The present invention encompasses methods of treating triple negative breast cancer and/or ovarian cancer using therapeutically effective amounts of compounds represented by the structure of formula I.
Wei LI, Duane D. MILLER, Shanshan DENG, Raya KRUTILINA, Tiffany N. SEAGROVES, Junming YUE, Guannan ZHAO, Wang QINGHUI, Mitchell S. STEINER
Filed: 14 May 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first